Tumor-derived biomimetic nanozyme with immune evasion ability for synergistically enhanced low dose radiotherapy

Chunyu Huang1†, Zeming Liu3†, Mingzhu Chen1, Liang Du1, Chunping Liu4, Shuntao Wang4, Yongfa Zheng2* and Wei Liu1*

Abstract

High doses of radiation can cause serious side effects and efficient radiosensitizers are urgently needed. To overcome this problem, we developed a biomimetic nanozyme system (CF) by coating pyrite (FeS₂) into tumor-derived exosomes for enhanced low-dose radiotherapy (RT). CF system give FeS₂ with immune escape and homologous targeting abilities. After administration, CF with both glutathione oxidase (GSH-OXD) and peroxidase (POD) activities can significantly lower the content of GSH in tumor tissues and catalyze intracellular hydrogen peroxide (H₂O₂) to produce a large amount of ·OH for intracellular redox homeostasis disruption and mitochondria destruction, thus reducing RT resistance. Experiments in vivo and in vitro showed that combining CF with RT (2 Gy) can provide a substantial suppression of tumor proliferation. This is the first attempt to use exosomes bionic FeS₂ nanozyme for realizing low-dose RT, which broaden the prospects of nanozymes.

Keywords: Low-dose radiotherapy, Tumor-derived exosomes, Pyrite nanozyme, Mitochondrial damage, GSH depletion
Introduction
Despite advances in scientific study, cancer, which can strike at any age, remains a severe threat to human life and health in today’s society [1–3]. Radiotherapy (RT) is used to keep almost half of all cancer patients alive, either alone or in combination with other innovative treatments [4–6]. From a mechanical standpoint, RT relies on the use of high-energy X-rays or gamma rays to cause radiation-induced DNA damage or to stimulate the formation of large amounts of toxic reactive oxygen species (ROS), of which about 90% are produced by mitochondria [7]. Cell apoptosis occurs when the rate of ROS synthesis exceeds the cell’s ability to neutralize these free radicals [8]. This allows tumor cells to be killed and the tumor to be abated. Long-term exposure to higher doses of radiation, on the other hand, can induce a variety of negative side effects, including fatigue, nausea and some digestive system diseases, etc. [9]. Furthermore, the tumor microenvironment (TME) in solid tumors exhibits high levels of GSH expression, which can inhibit antitumor RT [10, 11]. Moreover, because GSH is a reducing agent, it can directly eliminate ROS which reduces the effectiveness of ROS-based therapies [12]. Therefore, reducing GSH level can effectively improve RT efficacy. GSH elimination can be accomplished through a variety of pathways due to the various pathways of glutathione metabolism and the various types of chemical reactions involving glutathione, and converting glutathione to an oxidation state through direct interactions has become one of the most commonly used methods for reducing glutathione levels [12–14]. Bao et al. for example, created a composite nanomaterial containing MnO$_2$ to improve tumor hypoxia, alleviate and lower intracellular GSH levels, and therefore achieve radiation sensitization [15]. Qu et al. developed MoS$_2$@AIBI-PCM, a composite nanomaterial in which MoS$_2$ can efficiently produce
GSH oxidation without releasing hazardous metal ions, resulting in significant tumor death and good biocompatibility during therapy [16]. As a novel nano-materials, FeS\(_2\) nanozyme was verified to obtain both glutathione oxidase (GSH-OXD) and high-activity peroxidase (POD) [17]. Nanozymes have great advantages over natural enzymes [18–20]. FeS\(_2\) nanozyme can reduce GSH and catalyze H\(_2\)O\(_2\) to produce sufficient .OH to destroy mitochondria, which is expected to achieve a good synergistic effect combined with radiotherapy [21]. Despite the fact that these elements have proven effective against the GSH system, they are hardly to reach the tumor site [22]. These nanomaterials have a low immune escape capacity and are easily cleared by liver and kidney organs in the bloodstream; thus, their targeting ability and anti-tumor efficiency are considerably reduced [23, 24].

Cancer cell-derived exosomes (CDE) are endogenous vesicles ranging in size from 50 to 200 nm that are recovered from multivesicles or retrieved by incubating cell supernatants with appropriate separation kits [25–27]. Because they may be generated from tumor cells and are less likely to elicit a clearance response than manufactured drug delivery platforms, such vesicles, given by cancer cells themselves, provide improved drug delivery prospects [28–30]. Furthermore, exosomes have a high level of non-immunogenicity, making them resistant to phagocytosis by macrophages [31]. Exosomes are also simpler to penetrate from blood arteries to tumor tissues for precise medication administration or nanomaterial delivery [32]. Therefore, it stimulates us to coat nanozymes with CDE to overcome tumor RT resistance.

The combined application of FeS\(_2\) nanozyme and CDE to augment low-dose radiation was originally reported in this work. By coating FeS\(_2\) with CDE, a composite CF system was created (Scheme 1). Because CF has both homologous targeting and dual enzyme properties, the
Exosome membrane can enhance FeS₂ blood circulation time in vivo, and simultaneously help FeS₂ actively targeting to tumor tissues. Subsequently, FeS₂ nanozyme with GSH-OXD and POD activity can lower intracellular GSH levels. It catalyzes hydrogen peroxide in tumor cells to generate ·OH, which disrupts redox equilibrium and kills mitochondria, resulting in radiation sensitization. It’s important to mention that in the therapeutic process, we can get a powerful radiation sensitization with only 2 Gy of RT synergistic with CF, which is better than 6 Gy RT. CF system offers higher biological potential uses in the clinical. Finally, our findings broaden the use of exosomes and provide fresh insights into the development of exosome-based oncology therapeutic systems.

In this study, 4T1 cells were co-incubated with FeS₂ materials, and exosome separation kits were used to obtain exocytosed CF, which was then employed to build a CF system. Transmission electron microscopy (TEM) was used to confirm the successful production of CF material. Compared with pure FeS₂, CF was coated with a layer of exosome membrane with a small thickness (Fig. 1A, B), and this conclusion was further verified by western blotting assay (Fig. 1C). On the CDE membrane, the exosome protein markers CD63 and CD9 were identified [21, 28]. On CF loaded with FeS₂, the CD63 marker and another exosome marker (CD9) were also found, showing that the exosome membrane proteins on CF were not disturbed. Exosome membranes offer a lot of potential in the field of material delivery, and they’re a lot better than standard drug delivery systems like erythrocyte membranes that don’t have any targeting and don’t improve the amount of material that gets into tumor tissues [33]. In addition, during the three days of pure FeS₂ and CF stored in the phosphate buffer solution (PBS) environment (4 °C), their particle sizes almost did not change significantly. During the 3 days, the particle sizes of FeS₂ were 146.2 ± 1.6 nm, 152.6 ± 1.8 nm, and 151.0 ± 1.4 nm, respectively, while the particle sizes of CF were 153 ± 2.1 nm, 159.4 ± 2.5 nm, and 157.5 ± 1.9 nm (Fig. 1D), which also indicates that both FeS₂ and hybrid CF have good stability and can be used in subsequent biological experiments. This quality is unquestionably critical, as many materials have good properties, but their instability will prevent them from being used [34]. The Zeta potential of different particles was shown in Fig. 1E, with cancer cell vesicle (CV) and CF having zeta potentials of roughly about –23.1 and –22.6, respectively. We investigated POD-like activity of FeS₂ and CF based on the oxidation of 3,3′,5,5′-tetramethylbenzidine (TMB) in the presence of H₂O₂. The results show that both pure FeS₂ and FeS₂ encapsulated by exosome membrane can catalyze H₂O₂ to produce ·OH (Fig. 1F). These findings...
show that CF has an exosomal membrane structure and that it will be endocytosed into 4T1 tumor cells via extracellular action to alter the tumor microenvironment.

The CF system is well-structured and characterized in terms of performance. In vitro anti-tumor trials are currently underway. Although FeS$_2$ can alter the ecological balance of the cancer cells and so enhance the efficacy of radiation, it can only do so when it is present in the tumor tissue. The immune system may recognize diverse foreign invaders' stimuli, and a portion of that
stimulation can activate the immune response, resulting in immunity, while preventing other stimuli, resulting in tolerance [35]. Due to homology, which is connected to exosome membrane proteins, the immune system does not attack the exosomes released by cancer cells. Nanomaterial-coated exosomes can be directed to tumor cells, recognized by cancer cells, and engorged to release nano-material, whereas other drug delivery systems that do not have targeting capabilities. This internalization effect can be tracked by staining CF and red blood cell membranes coated FeS₂ (RF) nanovesicles with Dil dye and co-incubation with 4T1 cells and staining with commercial lysosome Lyso-Tracker Green probe to verify the ability of CF to be internalized by tumor cells in vitro (co-localization assay). For comparison, red cell membranes were coated with FeS₂ to form RF. After 2 h incubation, it was clear that a significant quantity of CF had been endocytosed, whereas RF only had a partial Dil fluorescent impact (Fig. 2A, B), demonstrating that exosomes might be employed as a perfect carrier of FeS₂ to target tumor tissues. As shown in Additional file 1: Figure S2, hemolysis assay verified that CF is stable in blood, indicating good biocompatibility of CF. In order to demonstrated the universality of exosome systems, we then prepared manganese dioxide nanzyme (MnO₂), as shown in Additional file 1: Figure S3, and used CDE to coat MnO₂ (CM) (Additional file 1: Figure S4). Furthermore, during the several days of MnO₂ and CM stored in the PBS environment (4 ℃), the diameter of MnO₂ and CM has barely changed (Additional file 1: Figure S5). MnO₂ has good catalase activity (CAT), which can catalyze H₂O₂ into O₂. CM also has good CAT activity, indicating that exosome membrane does not affect the enzyme activity (Additional file 1: Figure S6). Even at high concentrations, the number of MnO₂ swallowed by 4T1 cells was low (Additional file 1: Figure S8). As MnO₂ can achieve
radiotherapy sensitization by alleviating tumor hypoxic microenvironment, while CM can actively target cells, as shown in Additional file 1: Figure S7, the colony formation assays also proves that CM has better synergetic cell killing effect compared with MnO₂. Then, the changes of mitochondrial membrane potential (MMP) in tumor cells were monitored by JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-imidacarbocyanine) probe method. The JC dye normally builds up in the mitochondria, where it clumps together to give a red fluorescence. When mitochondria are injured and MMP levels are low, however, the JC monomer is released into the cytoplasm, resulting in green fluorescence [36]. Figure 2C demonstrates that cells treated with FeS₂ + RT had a high green/red fluorescence ratio, which is consistent with the reduced mitochondrial damage generated by FeS₂. FeS₂ will enter TME with twofold enzyme activity once CF is endocytosed by tumor cells, reducing GSH content while also catalyzing enough H₂O₂ to generate ·OH in situ, causing significant mitochondrial damage. Radiotherapy ought to be more sensitive as a result of mitochondrial injury. Double-stranded DNA breaks (DSB) in tumor cells when exposed to radiation, which provides insights into the radiation sensitization, and measuring the fluorescence intensity of γ-H2AX, is a good and intelligent way to verify the DSB formation after cell damage [37]. Therefore, we detected H2AX foci in the nucleus after treatment in different groups. After 2 Gy of radiotherapy, there was substantial DNA damage, and the DSB effect increased as the dose was increased. It’s important to mention that 2 Gy radiation mixed with RF only got about 40% γ-H2AX formation, but 2 Gy paired with CF got up to 76.8% γ-H2AX foci development. The synergistic effect of the targeting ability of the exosome membrane, the dual nano enzyme activity of FeS₂, and radiation sensitization was linked to the uniform and substantial difference between each experimental group. Furthermore, Colony formation assays revealed that the control group’s cell viability was largely unaltered, whereas the RT with RF group had moderate tumor growth inhibition (Fig. 2F). CF + RT system had the best tumor growth inhibition rate (90%), there are significant differences compared with each other experiment group, indicating that CF mediated improved ·OH content of TME can effectively exert influence on mitochondria and thus enhance the RT effect to realize tumor growth inhibition. Figure 2G also verifies that our FeS₂ has a good effect on GSH consumption. Together, these results drive our continued exploration of anti-tumor efficacy in vivo.

Given that in vitro testing of the tumor-killing action revealed significant potential. We investigate how CF effects can be amplified in vivo. As a result, we conducted in vivo pharmacokinetic studies to see how exosome membranes affect blood retention. Mice were given FeS₂, RF, or CF at a dose of 2.5 mg Fe/kg intravenously (Fig. 3A). Both RF and CF demonstrated a greater effect
on blood retention when compared to the pure FeS₂ group. Although the erythrocyte membrane coating protected from the attack of the immune system, it lacked tumor targeting, and the accumulation of FeS₂ in tumor tissues was only slightly increased, with the CF group having the most visible tumor accumulation. Following that, we investigated the biological dispersion (Fig. 3B). After 12 h of administration, the FeS₂ mainly accumulated in the liver and spleen of the FeS₂ group of mice, whereas the CF group demonstrated good tumor targeting and little organ accumulation, demonstrating the exosome membrane’s targeting capabilities. In order to verify the targeting ability of drugs-loaded exosomes, we conducted in vivo pharmacokinetic studies using DOX loaded erythrocyte exosomes (RBC-EXO@DOX) and CDE (CDE-EXO@DOX), respectively. Simultaneously, DOX loaded CF was prepared (CF@DOX). As shown in Additional file 1: Figures S9, S10, RBC-EXO@DOX and CDE both have long circulation. However, RBC-EXO@DOX accumulates less in tumor tissues compared with CDE-EXO@DOX and CF@DOX (Additional file 1: Figure S10). This result shows that tumor-derived exosomes have good tumor targeting. Following that, we looked at the efficacy of CF-mediated anti-tumor therapy in mice with 4T1 tumors. BALB/c mice were subcutaneously injected with $1 \times 10^6$ 4T1 cells into the right flank to determine the primary effect of the CF. When the primary tumor volume reached 200 mm³, the mice were divided into groups and treated. Tumor-bearing mice were divided randomly into 5 groups (each group included 5 mice): (1) control (PBS); (2) radiotherapy (RT, 2 Gy); (3) RF + RT; (4) high dose RT (6 Gy); (5) CF + RT. The FeS₂ concentration was 5 mg/kg in groups 3, and 5. For 16 days, the treatment was given every 4 days. The tumor volumes of the control and RT treated groups increased rapidly during the 2 weeks of treatment, as shown in Fig. 3C. The RF + RT group likewise had a nearly moderate tumor-suppressive effect. When these nanomaterials are injected into the caudal vein, when the RF circulates to the tumor tissue and is endocytosed by tumor cells, FeS₂ is released to the TME, playing the equivalent therapeutic impact. The CF + RT system, which included both FeS₂, had the most potent therapeutic impact, with tumor volume growth curves nearly totally suppressed during therapy. The tumor mass in mice was also consistent with the volume curve (Fig. 3D). No weight changes were detected in the treatment group during this study, indicating that the treatment did not cause any significant systemic toxicity (Fig. 3E), which is significant because many treatments are associated with extremely systemic toxicity, which is extremely detrimental to the future clinical application of the material. We collected tumor tissue slices for staining. TUNEL and H&E staining (Fig. 3F) indicated the presence of a high level of cell necrosis in the CF combined RT therapy group. Furthermore, as shown in Fig. 4, after the treatment of mice’s vital organs (heart, liver, spleen, lungs, and kidney) without any inflammation and damage in the body, liver, and kidney indices were also normal. Many nanomaterials have high therapeutic efficacy, however, they are also associated with systemic toxicity, limiting their future clinical applications. The in vivo results show that our innovative combined therapy not only achieves an excellent therapy with biological safety but also enhances tumor ·OH content and reinforces the effect of RT with substantial CF-enhanced therapy.

**Conclusion**

Finally, we developed a unique oxidative stress destroyer to enable better radiotherapy. The CF can decrease the content of GSH in the tumor microenvironment and catalyze H₂O₂ to produce a large amount of ·OH, the exosome membrane can render FeS₂ with admirable homologous targeting ability, and all of these elements have an enhanced ability to low-dose RT. Both the in vitro and in vivo studies suggest that our method has a good tumor inhibition effect. Importantly, during treatment, our prepared system showed no evident side effects. In the future, we will continue to investigate the biological applications of the combination of FeS₂ and other unique vehicles, as well as refine our treatment strategy by incorporating additional nanotechnology and new technologies.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12951-021-01182-y.

---

**Additional file 1:**

**Figure S1.** Nanoparticle uptake by RAW 264.7 cells at different incubated concentration (FeS₂ dose of 25, 50 and 100 μg/mL). Data are presented as mean ± SD (n = 3). **Figure S2.** Hemolysis ratio of CF at different FeS₂ concentrations. **Figure S3.** TEM image of MnO₂. **Figure S4.** TEM image of CM. **Figure S5.** Statistical graph of the measured diameter of MnO₂ and CM. Data are presented as mean ± SD (n = 3). **Figure S6.** Oxygen generation under different conditions measured using a dissolved oxygen meter. **Figure S7.** Nanoparticles uptake by 4T1 cells at different concentration. Data are presented as mean ± SD (n = 3). **Figure S8.** Colony formation assays were conducted using 4T1 cells with different treatment (n = 3). **Figure S9.** Pharmacokinetic behavior of RBC-EXO@DOX, CDE-EXO@DOX, and CF@DOX in mice following i.v. administration. Data are presented as mean ± SD (n = 3). **Figure S10.** Quantitative analysis of DOX biodistribution in tissues and tumors of tumor-bearing mice injected with different formulations. Data are presented as mean ± SD (n = 3).

**Acknowledgements**

This work was supported by the National Natural Science Foundation of China (Grant No. 81703035, No. 31971166). This work was supported by Key Projects of Science and Technology to Help the Economy 2020 (Grant No. SQ20201FF042643), the Basic Research Projects of Shenzhen Knowledge Innovation Program (JCYJ20180302173424902), and the Frontier Projects of
References

1. Zhu D, Lu M, Jiang W, Suo M, Huang Q, Li K. A biomimetic nanozyme/camptothecin hybrid system for synergistically enhanced radiotherapy. J Mater Chem B. 2020;8(24):5312–9.

2. Gao F, Tang Y, Liu W, Zou MZ, Huang C, Liu CJ, Zhang XZ. Intra-extra-cellular lactic acid exhaustion for synergistic metabolic therapy and immunotherapy of tumors. Adv Mater. 2019;31(51):1904639.

3. Liu LH, Zhang YH, Qiu WX, Zhang L, Gao F, Li B, Xu L, Fan JX, Li ZH, Zhang XZ. Dual-stage light amplified photodynamic therapy against hypoxic tumor based on an O₂ self-sufficient nanoplatorm. Small. 2017;3(7):1701621.

4. Song G, Cheng L, Chao Y, Yang K, Liu Z. Emerging nanotechnology and advanced materials for cancer radiation therapy. Adv Mater. 2017;29(32):1700996.

5. Liu T, Yang K, Liu Z. Recent advances in functional nanomaterials for X-ray triggered cancer therapy. Prog Nat Sci. 2020;30(5):567–76.

6. Xie J, Gong L, Zhu S, Yong Y, Gui Z, Zhou Y. Emerging strategies of nanomaterial-mediated tumor radiosensitization. Adv Mater. 2019;31(3):1802244.

7. Li N, Yu L, Wang J, Gao X, Chen Y, Pan W, Tang B. A mitochondria-targeted nanoradiosensitizer activating reactive oxygen species burst for enhanced radiation therapy. Chem Sci. 2018;9(12):5159–64.

8. Noh J, Kwon B, Han E, Park M, Yang W, Cho W, Yoo W, Khang G, Lee D. Amplification of oxidative stress by a dual stimuli-responsive hybrid drug enhances cancer cell death. Nat Commun. 2015;6:6907.

9. Rocca JD, Werner ME, Kramer SA, Huxford-Phillips RC, Sukumar R, Cummings ND, Vivero-Escotó JL, Wang AZ, Lin W. Polysiloxanes nanotweeter for triggered release of cisplatin and effective cancer chemoradiotherapy. Nanomedicine. 2015;11(1):31–8.

10. Yin W, Li J, Ke W, Zha Z, Ge Z. Integrated nanoparticles to synergistically elevate tumor oxidative stress and suppress anti-oxidative capability for amplified oxidation therapy. ACS Appl Mater Interfaces. 2017;9(55):29538–46.

11. Cheng X, Xu HD, Ran HH, Liang G, Wu FG. Glutathione-depleting nanomedicines for synergistic cancer therapy. ACS Nano. 2021;15(9):8039–68.

12. Lan J-S, Liu L, Zeng R-F, Qin Y-H, Hou J-W, Wei S-S, Yue S, Yang J, Ho RVJ, Ding Y, Zhang T. Tumor-specific carrier-free nanodrugs with GSH depletion and enhanced ROS generation for endogeneous synergetic anti-tumor by a chemotheraphy-photodynamic therapy. Chem Eng J. 2021;407(1):127212.

13. Liu Y, Zhai S, Jiang X, Liu Y, Wang K, Wang C, Zhang M, Liu X, Bu W. Intracellular mutual promotion of redox homeostasis regulation and iron metabolism disruption for enduring chemodynamic therapy. Adv Funct Mater. 2021;31(17):2101090.

14. Wu Y, Guo T, Qiu Y, Lin Y, Yao Y, Liu W, Lin L, Song J, Yang H. An inorganic prodrug, tellurium nanowires with enhanced ROS generation and GSH depletion for selective cancer therapy. Chem Sci. 2019;10(29):7068–75.

15. Lyu M, Zhu D, Kong X, Yang S, Ding S, Zhou Y, Quan H, Duo Y, Bao Z. Glutathione-depleting nanoenzyme and glucose oxidation combination for hypoxia modulation and radiotherapy enhancement. Adv Healthc Mater. 2020;9(11):e1901819.

16. Wu S, Liu X, Ren J, Xu Q. Glutathione depletion in a benign manner by MoS2-based nanoflowers for enhanced hypoxia-irrelevant free-radical cancer therapy. Small. 2019;15(5):e1904870.

17. Meng X, Li D, Chen L, He H, Wang Q, Hong C, He J, Gao X, Yang Y, Jiang B, Nie G, Yan X, Gao L, Fan K. High-performance self-cascade pyrite nanomaterials for apoptosis-ferroptosis synergistic tumor therapy. ACS Nano. 2021;15(3):5735–51.

18. Zhu D, Zheng Z, Luo G, Suo M, Li X, Duan Y, Tang BZ. Single injection and multiple treatments: an injectable nanozyme hydrogel as AIEgen reservoir and release controller for efficient tumor therapy. Nano Today. 2021;37:1/1091.

19. Zhang R, Yan X, Fan K. Nanomaterials inspired by natural enzymes. Acc Mater Res. 2021;2(7):534–47.

20. Tang G, He J, Liu J, Yan X, Fan K. Nanozyme for tumor therapy: surface modification matters. Exploration. 2021;11(1):75–89.

21. Zhu D, Liu Z, Li Y, Huang Q, Xia L, Li K. Delivery of manganese carbonyl to the tumor microenvironment using tumor-derived exosomes for cancer gas therapy and low dose radiotherapy. Biomaterials. 2021;274:120894.

22. Zhu Y, Shi H, Li T, Yu J, Guo Z, Cheng J, Liu Y. A dual functional nanoreactor for synergetic starvation and photodynamic therapy. ACS Appl Mater Interfaces. 2020;12(33):36928–37.

23. Rao L, Meng QF, Bu LL, Cai B, Huang Q, Sun Zi, Zhang WF, Li A, Guo SS, Liu W, Wang TH, Zhao XZ. Erythrocyte membrane-coated upconversion nanoparticles with minimal protein adsorption for enhanced tumor imaging. ACS Appl Mater Interfaces. 2017;9(3):2159–68.

24. Su J, Sun H, Meng Q, Zhang Z, Yin Q, Li Y. Enhanced blood suspensi-bility and laser-activated tumor-specific drug release of theranostic mesoporous silica nanoparticles by functionalizing with erythrocyte membranes. Theranostics. 2017;7(3):523–37.

25. Wang D, Yao Y, He J, Zhong X, Li B, Rao S, Yu H, He S, Feng X, Xu T, Yang B, Yong T, Gan L, Hu J, Yang X. Engineered cell-derived microparticles Bi2Se3/DOX@MPs for imaging guided synergistic photothermal/low-dose chemotherapy of cancer. Adv Sci. 2020;7(3):1901293.

26. Yang Z, Shi J, Xie J, Wang Y, Sun Y, Liu T, Zhao Y, Zhao X, Wang X, Ma Y, Kong C, Jiang D, Chen W, Chen Y, Fu Y, Kwak KJ, Fan Y, Kang C, Yin C, Rhe J, Bertani P, Otero J, Lu W, Yun K, Lee AS, Jiang W, Teng L, Kim BY, Lee LJ. Large-scale generation of functional mRNA-encapsulating exosomes via cellular modification nanoplatorm. Nat Biomed Eng. 2020;4(1):69–83.

27. Ja G, Han Y, An Y, Ding Y, He C, Wang X, Tang Q. NRP-1 targeted and cargo-loaded exosomes facilitate simultaneous imaging and therapy of glioma in vitro and in vivo. Biomaterials. 2018;178:302–16.

28. Guo W, Li Y, Peng W, Shen H. Exosomes: a potential therapeutic tool targeting communications between tumor cells and macrophages. Mol Ther. 2020;28(9):1953–64.

29. Zhu D, Duo Y, Meng S, Zhao Y, Xia L, Zhang Z, Li Y, Tang BZ. Tumor-exocytosed exosome/aggeregation-induced emission luminoen hybrid nanoparticles facilitate efficient tumor penetration and photodynamic therapy. Angew Chem. 2020;59:2–10.

30. Zhu D, Lu M, Huang Q, Suo M, Liu Y, Jiang W, Duo Y, Fan K. Stellate plasmic exosomes for penetrative targeting tumor NIR-II thermo-radiotherapy. ACS Appl Mater Interfaces. 2020;12(33):36928–37.

31. Zhu DM, Duo YH, Suo M, Zhao YH, Xia LG, Zheng Z, Li Y, Tang BZ. Tumor-exocytosed exosome/aggeregation-induced emission luminoen hybrid nanoparticles facilitate efficient tumor penetration and photodynamic therapy. Angew Chem-Int Edit. 2020;59(33):13836–43.
32. Yong T, Zhang X, Bie N, Zhang H, Zhang X, Li F, Hakeem A, Hu J, Gan L, Santos HA, Yang X. Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy. Nat Commun. 2019;10(1):3838.
33. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110(1):13–21.
34. Ouyang J, Deng L, Chen W, Sheng J, Liu Z, Wang L, Liu YN. Two dimensional semiconductors for ultrasound-mediated cancer therapy: the case of black phosphorus nanosheets. Chem Commun. 2018;54(23):2874–7.
35. Liu Y, Zhen W, Wang Y, Song S, Zhang H. Na2S2O8 nanoparticles trigger antitumor immunotherapy through reactive oxygen species storm and surge of tumor osmolarity. J Am Chem Soc. 2020;142(52):21751–7.
36. Fu S, Yang R, Zhang L, Liu W, Du G, Cao Y, Xu Z, Cui H, Kang Y, Xue P. Biomimetic CoO@AuPt nanozyme responsive to multiple tumor microenvironmental clues for augmenting chemodynamic therapy. Biomaterials. 2020;257:120279.
37. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011;11(4):239–53.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.